FDA Signals Greater Use of Real-World Evidence

Clinical Trials Advisor
A A
The FDA is committed to using real-world evidence in drug approvals and post-market evaluations, and forthcoming guidance will describe RWE and its potential for satisfying FDA’s pre- and post-market requirements.

To View This Article:

Login

Subscribe To Clinical Trials Advisor